Skip to main content

RenovoRx, Inc.

RNXT
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001574094

In the last 90 days, RenovoRx, Inc. insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q3 2026, worth $19.1M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$54.0M
Insider buysLast 90 days, $46.5K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +12 vs. previous quarter
40
13F valueReported value at the end of Q3 2026
$19.1M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$1.12M
+2,511.6% year over year
Net income, FY2025
-$11.2M
No comparable prior period
Free cash flow, FY2025
-$11.0M
No comparable prior period
Revenue, Q3 FY2026
$1.07M
+300.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $11.2M (994.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
998.0K
Shares sold short
Change
+133.4K
+15.4% vs. previous
Days to cover
3.51
At average daily volume

Superinvestors holding RNXT, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding RNXT at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by RenovoRx, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)6:30 AM ETNov 161 dayAgah RamtinExecutive Chairman and CMOPPurchase+50.0K$0.9297+$46.5K+6.3%848.5K after
May 21, 2026 (view filing)May 192 daysVoll MarkChief Financial OfficerPPurchase+25.0K$0.79+$19.8K+21.3%142.4K after
Mar 24, 2026 (view filing)Mar 204 daysMarton LaurenceDirectorPPurchase+9.72K––New position9.72K after
Mar 24, 2026 (view filing)Mar 204 daysMarton LaurenceDirectorPPurchase+4.86K–––4.86K afterDerivative
Mar 24, 2026 (view filing)Mar 204 daysBagai ShaunChief Executive OfficerPPurchase+24.3K––+8.4%313.4K after
Mar 24, 2026 (view filing)Mar 204 daysBagai ShaunChief Executive OfficerPPurchase+12.2K–––12.2K afterDerivative
Mar 24, 2026 (view filing)Mar 204 daysVoll MarkChief Financial OfficerPPurchase+97.2K––New position97.2K after
Mar 24, 2026 (view filing)Mar 204 daysVoll MarkChief Financial OfficerPPurchase+48.6K–––48.6K afterDerivative
Jan 22, 2026 (view filing)Jan 211 dayAgah RamtinChief Medical OfficerPPurchase+10.0K$1.00+$10.0K+1.3%798.5K after
Jan 5, 2026 (view filing)Dec 31, 20255 daysAgah RamtinChief Medical OfficerPPurchase+9.79K$0.86+$8.42K+1.3%788.5K after

Top 10 13F holders, Q3 2026

See all 40 holders

The largest institutional positions in RenovoRx, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding RNXT in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
AIGH Capital Management LLC4,263,622$6.65M0.76%−141,817−3.2%Reduced
Vanguard Capital Management LLC1,668,360$2.60M0.00%+224,618+15.6%Added
Bleichroeder LP1,666,098$2.60M0.26%00.0%Unchanged
Renaissance Technologies LLC1,119,749$1.75M0.00%+1,108,349+9,722.4%Added
Geode Capital Management, LLC473,093$738.1K0.00%+48,945+11.5%Added
State Street Corp314,636$490.8K0.00%+288,484+1,103.1%Added
EAM Investors, LLC272,706$425.4K0.04%+272,706New
Vanguard Fiduciary Trust Co269,916$421.1K0.00%+29,586+12.3%Added
Walleye Capital LLC262,106$408.9K0.00%+262,106New
Wealthspire Advisors, LLC252,525$393.9K0.00%00.0%Unchanged

Holders of 5% or more of RNXT

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of RenovoRx, Inc..

Largest holders of RNXT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Hirschman Orin13G/A9.80%4.43M shares+2.70 ppfrom 7.10%May 8, 20254 filingsApr 27, 2026SEC